TY  - JOUR
TI  - Ustekinumab
AB  - Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12) 
and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found 
remarkable in real-world experiences. Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted 
according to body weight and its administration every 12 weeks in the maintenance period.
AU  - borlu, murat
DO  - 10.4274/turkderm.galenos.2022.63139
PY  - 2022
JO  - Türkderm Türk deri hastalıkları ve frengi arşivi
VL  - 56
IS  - 1
SN  - 2717-6398
SP  - 48
EP  - 51
DB  - TRDizin
UR  - http://search/yayin/detay/534073
ER  -